CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 239 enrolled
Drug / intervention
Voriconazole or posaconazoledrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02714504
NCT02714504N/ACompleted
CompareCT.gov

Evaluation of the Efficacy of Anti-mold Azole Prophylaxis in High-risk Hematologic Patients With Baseline Superficial Skin Lesions Positive for Fusarium Spp

Universidade Federal do Rio de Janeiro·interventional·Posted Mar 21, 2016·Updated Sep 21, 2018

In Brief

A clinical study evaluating Voriconazole or posaconazole for Fusariosis and Onychomycosis. Completed, enrolled 239 participants across 1 site.

Detailed Summary

Patients admitted for autologous or allogeneic hematopoietic cell transplantation, induction-remission chemotherapy for acute myeloid leukemia, myelodysplasia or acute lymphoid leukemia, or to receive immunosuppressive therapy for aplastic anemia will be screened with dermatologic examination. In the presence of any skin lesion in the extremities, direct exam and fungal culture will be performed. If these exams indicate the presence of Fusarium species, patients will receive anti-mold azole prophylaxis

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFusariosis, Onychomycosis
CountriesBrazil
Collaborators--

Timeline

N/ACompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 21, 2016
Enrollment StartAug 1, 2008
Primary CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 6.3 yearsPosted 10.3 years ago

Interventions

Voriconazole or posaconazoledrug

Azole with activity against molds